Luis, Supply Chain at Apellis
Caring fiercely
so Michele, who is living with PNH, can spend more time riding her beloved horse
Get to know us
We are a global biotechnology company leveraging compassion, creativity and courageous science to deliver life-changing medicines.
At the heart of our company is the belief that advanced science can move hand in hand with genuine compassion. Our goal is to find solutions that lift the burden of PNHParoxysmal nocturnal hemoglobinuria (PNH)A rare and chronic disease in which the body attacks and destroys its own red blood cells, which may result in anemia and blood clots. This process, called hemolysis, can lead to symptoms including fatigue, weakness, headaches, chest pain, abdominal pain and others. for the many people battling it on a daily basis, and to do so with respect, transparency and integrity.
The way it’s always been done is not the way we do things at Apellis. We believe making a meaningful difference means approaching work differently – with openness, boldness, creativity and humility. Everything we do begins with a simple question: What if?
Exploration and courage are core parts of who we are, and that applies to our science as well. By targeting the C3c3A protein located in the blood that acts as a central point of the complement system, regulating its activation and any associated inflammation, extravascular hemolysis, and, ultimately, intravascular hemolysis. protein, we hope to develop medicines for a broad range of devastating diseases caused by the over-activation of the complement cascade, a key part of the immune system.
Our work focuses on a specific protein called C3.
C3 acts as a “central hub” of the complement system – the part of the immune system responsible for the symptoms of PNH. Since C3 is the protein that “kicks off” the immune system response, we believe inhibiting C3 may be a way to help people with PNH.
